Nanoscientist to develop new microsystem for more efficient drug-testing

NewsGuard 100/100 Score

A University of Southampton nanoscientist is working on a new microsystem for more efficient testing of pharmaceutical drugs to treat diseases such as cystic fibrosis, MG (myasthenia gravis) and epilepsy.

Dr Maurits de Planque of ECS-Electronics and Computer Science at the University will develop a new method to investigate the ion channels that underlie these serious disorders and that are used to test the effectiveness of new drugs.

"At the moment, commercial testing of new drugs is carried out using ion channels in living cell membranes. This is a slow and difficult process, not least because producing too many channels actually kills the cells," said Dr de Planque

The researchers therefore plan to produce these ion channels without using cells, which is possible with so-called cell-free expression mixtures, and to insert the channels in a very stable artificial cell membrane which should enable faster, less expensive drug testing.

"Researchers have experimented with cell-free mixtures before, but they found that this method was not economical due to the amount of expensive biochemicals required," said Dr de Planque. "Our proposal to develop a new platform, which uses a couple of microlitres instead of millilitres, will be a very cost-effective way of doing this, particularly when the produced channel is directly inserted in a membrane for drug testing."

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Yokogawa helps to revolutionize the field of single-cell lipidomics